Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

425
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
425
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

554
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
554
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

557
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

618
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
618
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

474
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
474
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to 'Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials'. Retraction notice to AJOGMF Volume 6, Issue 10/ October 2024/ 101459.

American journal of obstetrics & gynecology MFM·2026
Same author

Association of Prepregnancy Obesity and Excessive Gestational Weight Gain with Perinatal Outcomes among Patients with Pregestational Diabetes.

American journal of perinatology·2026
Same author

Identification of de novo variants from parent-proband duos via long-read sequencing.

American journal of human genetics·2026
Same author

Acute Fatty Liver of Pregnancy and Fetal Fatty Acid Oxidation Disorders: A Systematic Review.

O&G open·2026
Same author

Hereditary Anemias as a Monogenic Etiology for Nonimmune Hydrops Fetalis.

Clinical therapeutics·2026
Same author

First-Trimester Machine Learning to Predict Preeclampsia in Normotensive Pregnancies by American Heart Association Guidelines.

American journal of perinatology·2026

Related Experiment Video

Updated: Jun 17, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K

Propranolol to decrease time to delivery: a meta-analysis of randomized controlled trials.

Sonia Biswas1, Mariella Toro2, Rebecca Horgan3

  • 1Department of Obstetrics and Gynecology, Monmouth Medical Center, Long Branch, NJ (Biswas).

American Journal of Obstetrics & Gynecology MFM
|August 8, 2024
PubMed
Summary
This summary is machine-generated.

Propranolol use during labor induction significantly shortens delivery time by approximately 91 minutes. However, it did not significantly reduce delivery time for labor augmentation, with no increased risks observed.

Keywords:
augmentationbeta-blockerinductionlaborpropranolol

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K

Related Experiment Videos

Last Updated: Jun 17, 2025

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.0K

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Clinical Trials

Background:

  • Induction of labor (IOL) and augmentation of labor are common obstetric interventions.
  • The role of beta-blockers like propranolol in modifying labor duration is of clinical interest.
  • Evidence on propranolol's effect on time to delivery requires synthesis.

Purpose of the Study:

  • To evaluate the impact of propranolol on the time to delivery in patients undergoing labor induction or augmentation.
  • To synthesize findings from randomized controlled trials (RCTs) on propranolol's efficacy and safety in labor.

Main Methods:

  • Comprehensive literature search of PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, and CINAHL up to December 2023.
  • Inclusion of RCTs comparing propranolol with placebo or standard care for induction or augmentation.
  • Exclusion of non-randomized trials, observational studies, and studies with non-standard control groups.

Main Results:

  • Nine RCTs involving 1,182 patients were analyzed.
  • Propranolol significantly reduced time to delivery during labor induction (MD, -91.5 minutes; 95% CI -110.6 to -72.4).
  • No significant reduction in time to delivery was observed during labor augmentation (MD, -2.98 minutes; 95% CI -21.6 to 15.6).
  • Pooled analysis showed a mean reduction of 46.15 minutes (95% CI -59.48 to -32.81) for IOL and augmentation combined.
  • No increased risk of postpartum hemorrhage, blood transfusion, cesarean delivery, or NICU admission was associated with propranolol use.

Conclusions:

  • Propranolol use effectively shortens the time to delivery by about 91 minutes when used for labor induction.
  • Propranolol does not significantly decrease delivery time when used for labor augmentation.
  • The use of propranolol during labor induction and augmentation is not associated with increased adverse maternal or neonatal outcomes.